Presented by:

Alex Plesa, PhD

Scientist I, Wyss Institute at Harvard University

Harvard's Office of Technology Development and LabCentral invite you to the latest event in the Guppy Tank series, where Harvard life-science innovators will pitch their early-stage concepts to a panel of entrepreneurs and investors for constructive, in-depth feedback.

Please join us on Tuesday, April 29 from 4:00 to 6:00 p.m. at LabCentral to hear the presentation, learn from experts on startup formation, and participate in giving audience feedback. The event is accompanied by a reception with food and drinks. All are welcome!

Dr. Plesa welcomes constructive feedback from the Guppy Tank panelists, and from the audience, on the commercialization strategy for this innovation.

Register Here

The Panel:

Christian Schroeder Kaas - Principal Scientist and Nucleic Acid Research Focus Group Chair at Novo-Nordisk

Ja Young Kim-Muller - Innovation Lead at Bio-Innovation Hub at Novo-Nordisk

Mike Schlabach - Senior Vice President and Chief Scientific Officer at Curie.Bio

Steve Tregay - Managing Partner at Mission BioCapital

About the Project:

A major limitation in chronic disease treatment is the incomplete understanding of how cell states change during disease progression. As a result, most therapies target downstream effects of dysfunction, rather than the upstream regulators, leading to limited efficacy and high failure rates in clinical translation. Without a clear map of the molecular events that drive cells from healthy to diseased states and an understanding of the central regulators orchestrating these transitions, effective interventions that restore cellular health remain out of reach.

Regula Bio, a spin-out from the Wyss Institute, is pioneering a new approach by using patient-derived multiomic data to map cell transitions from healthy to dysfunctional states across chronic diseases. By integrating AI-driven computational modeling with high-throughput screening, Regula Bio identifies key regulators that can convert dysfunctional cells back to healthy states, unlocking transformative therapies for complex, chronic conditions. With a mission to create actionable maps of cellular dysfunction, we are building a pipeline of next-generation therapies designed to restore cell health and resilience across multiple chronic diseases. The company’s first therapeutic asset significantly reduced liver fibrosis in preclinical studies and shows potential as a pan-organ anti-fibrotic therapy. Regula Bio is currently developing this lead program as an mRNA-LNP therapeutic for liver fibrosis while expanding its pipeline to target a broad range of chronic diseases by addressing the root regulators of cellular dysfunction.